A14S0X verse

Verseon to Present Preclinical Data on Novel Anticancer Candidates for Use against Multidrug Resistant Cancers

FREMONT, Calif.--(BUSINESS WIRE)--

Verseon will present preclinical data on its novel anticancer drug candidates, which have shown promising results in preliminary testing against tumor cell lines resistant to major chemotherapy agents. The results will be shown at the BIO-Europe conference held in Berlin from November 6–8, 2017.

Cancer still remains a primary concern with almost 1.7 million people in the US newly diagnosed with some form of cancer in 2016. Currently, chemotherapy is essential to the treatment of most cancers. However, tumors in many patients become resistant to chemotherapy agents over time, limiting the effectiveness of available drugs.

Dr. Anirban Datta, Verseon’s Director of Discovery Biology, will present the first preclinical results on a new class of anticancer agents, which are potent against a range of cancer cell lines in cell-based assays. In particular, he will highlight the effectiveness of these new drug candidates against cancer cell lines resistant to established chemotherapy agents.

“We are really excited about these results as they show that our novel chemotherapy agents are largely unaffected by mechanisms of multidrug resistance. This fills an important need for the treatment of many cancers, especially for patients with recurrent solid tumors,” said Dr. Datta.

Verseon uses its innovative computer-driven drug discovery platform to generate new drug candidates for a variety of indications. This platform provides access to many more drug-like molecules than are available to conventional pharmaceutical companies. Verseon currently has active programs in anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

Details of the presentation are as follows:

Date: Tuesday, November 7, 2017

Time: 5:15 PM

Location: CityCube Berlin, Room M3 on Level 3

About Verseon

Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

www.verseon.com

- Ends -

EN
31/10/2017

Underlying

A14S0Xverse

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on verse

 PRESS RELEASE
Free
A14S0X VERSE

Verseon Showcases Candidates for Next-Generation Diabetic Eye Disease ...

FREMONT, Calif.--(BUSINESS WIRE)-- presented their oral drug candidates for diabetic macular edema (DME) at this week’s 2019 BIO International Convention in Philadelphia. These drug candidates could become the first real alternative to eye injections, the current standard of care for millions of diabetics at risk of vision loss. “Our oral development candidate has the potential to redefine how DME is treated,” said Dr. Anirban Datta, Verseon’s Senior Director of Discovery Biology. “Not only could it replace inconvenie...

June 4, 2019 1 EN
 PRESS RELEASE
Free
A14S0X VERSE

Verseon Presents Oral Drug Candidate for Diabetic Eye Disease That Cou...

FREMONT, Calif.--(BUSINESS WIRE)-- Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s in Vancouver. This new drug candidate for oral dosing could lead to the first real alternative to eye injections, the current standard of care for millions of diabetics at risk of losing their eye sight. Diabetic macular edema (DME) is a leading cause of adult blindness, affecting about one in three long-term diabetes patients. Wi...

April 30, 2019 1 EN
 PRESS RELEASE
Free
A14S0X VERSE

Verseon Pioneers New Way of Funding Innovation Through Security Token ...

FREMONT, Calif.--(BUSINESS WIRE)-- is launching a security token offering (STO) aiming to set a new standard for the 21st century public offering to a globally connected investor base. To make its STO available to investors around the globe, Verseon will use the technology and services of its subsidiary Using its innovative, computationally driven drug discovery platform, clinical-stage pharmaceutical company Verseon has built a rapidly growing pipeline of unique drug candidates across multiple disease areas. ...

March 18, 2019 1 EN
 PRESS RELEASE
Free
A14S0X VERSE

Verseon Presents Two Precision Oral Anticoagulants with Low Bleeding a...

FREMONT, Calif.--(BUSINESS WIRE)-- Technology-based pharma company Verseon presented two lead candidates from its new class of precision oral anticoagulants (PROACs) at last week’s in Honolulu, HI. The new drug candidates, products of Verseon’s computationally driven drug discovery platform, could become the first anticoagulants suitable for long-term co-administration with antiplatelet drugs for patients with coronary artery disease. Millions of patients worldwide could benefit from safe, long-term therapy combining an oral...

February 11, 2019 1 EN
 PRESS RELEASE
Free
A14S0X VERSE

Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral An...

FREMONT, Calif.--(BUSINESS WIRE)-- Verseon’s phase 1 trial in healthy volunteers, which started dosing last week, could lead to a new treatment standard for millions of cardiac patients who would benefit from long-term therapy with both antiplatelet and anticoagulant drugs. Current anticoagulants (NOACs, novel oral anticoagulants) substantially increase major bleeding events, a potentially fatal side effect, especially when they are administered together with antiplatelet drugs. Preclinical studies found that Verseon’s PROACs...

February 4, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch